{"id":41989,"date":"2025-09-22T15:46:28","date_gmt":"2025-09-22T07:46:28","guid":{"rendered":"https:\/\/flcube.com\/?p=41989"},"modified":"2025-09-22T15:46:29","modified_gmt":"2025-09-22T07:46:29","slug":"chinas-insilico-mabwell-and-chemexpress-forge-ai%e2%80%91driven-adc-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41989","title":{"rendered":"China\u2019s Insilico, Mabwell, and Chemexpress Forge AI\u2011Driven ADC Collaboration"},"content":{"rendered":"\n

Insilico Medicine<\/strong>, a global leader in generative AI\u2011driven drug discovery, announced a strategic partnership with Mabwell Bioscience<\/strong> (SHA: 688062<\/a>) and Shanghai Haoyuan Chemexpress Co. Ltd.<\/strong> (SHA: 688131<\/a>). The three companies will jointly build a next\u2011generation antibody\u2011drug conjugate (ADC) library spanning hundreds of targets, with the goal of accelerating industrialization and commercialization of innovative ADC therapeutics.<\/p>\n\n\n\n

Partnership Architecture<\/h2>\n\n\n\n
Component<\/th>Provider<\/th>Contribution<\/th><\/tr><\/thead>
Antibody Portfolio<\/strong><\/td>Mabwell<\/td>Hundreds of monoclonal & bispecific antibodies targeting oncology & autoimmunity antigens<\/td><\/tr>
ADC Platform<\/strong><\/td>Mabwell<\/td>Proprietary conjugation technology and scalable manufacturing<\/td><\/tr>
AI Analysis<\/strong><\/td>Insilico<\/td>Pharma.AI platform for disease\u2011mechanism, target\u2011characteristic, and toxicology modeling<\/td><\/tr>
Payload & Linker Library<\/strong><\/td>Chemexpress<\/td>Extensive small\u2011molecule building blocks and tool compounds for ADC synthesis<\/td><\/tr>
End\u2011to\u2011End Service<\/strong><\/td>All<\/td>From hit\u2011to\u2011lead screening through pre\u2011clinical and clinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

AI\u2011Enabled Design Pipeline<\/h2>\n\n\n\n